Negara: Inggris
Bahasa: Inggris
Sumber: MHRA (Medicines & Healthcare Products Regulatory Agency)
Trazodone hydrochloride
Teva UK Ltd
N06AX05
Trazodone hydrochloride
50mg
Oral capsule
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04030100; GTIN: 5017007011736
• weight loss • difficulty in sleeping, unusual behaviour (overexcited), nervousness, agitation, nightmares, reduced sexual desire • feeling confused, restless, sweating, tremor (shaking), shivering, hallucinations (strange visions or sounds), sudden jerks of the muscles or a fast heart beat. You may have something called Serotonine syndrome. • convulsion/fits • feeling very unwell possibly with shortness of breath (dyspnoea), difficulty in walking or walking with a shuffling gait, shaking, uncontrolled muscle twitching, and a high temperature (above 38ºC). This could be a rare case of neuroleptic malignant syndrome. • dizziness, headache, drowsiness (this should wear off as you continue to take Trazodone) • eyesight problems, decreased alertness, memory disturbances • swelling of the brain, loss of the ability to speak or write • unusual skin sensations such as numbness, tingling, pricking, burning or creeping on the skin (paraesthesia) • abnormal muscle rigidity • altered taste • rapid or slow heart rate • fall in blood pressure on standing up which causes dizziness, light-headedness or fainting, increase in blood pressure • nausea, vomiting, dry mouth • constipation, diarrhoea, indigestion, inflammation and pain of stomach, increased salivation, paralysis of intestine • liver problems such as jaundice (yellowing of the skin and whites of the eyes caused by liver or blood problems) and liver damage • skin rash, itching, increased perspiration • joint pain, pain in the limbs, back pain, muscle pain • urinary disorders • long-lasting painful erections • weakness, oedema, fatigue, chest pain, fever • elevated liver enzymes • heart problems. REPORTING OF SIDE EFFECTS If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard By reporting side effects you can help provide more information on the safe Baca dokumen lengkapnya
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Trazodone 50 mg Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 50mg of trazodone hydrochloride Excipient with known effect Each capsule contains 77.660 mg of Lactose monohydrate For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, hard 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Relief of symptoms in all types of depression, including accompanied by anxiety. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology DEPRESSION: Adults: Initially 150mg/day in divided doses after food or as a single dose on retiring. This may be increased up to 300mg/day in single or divided doses. The major portion of a divided dose to be taken on retiring. The dose may be further increased to 600mg/day in divided doses in hospitalised patients. Elderly: For very elderly or frail patients the recommended initial starting dose is reduced to 100mg/day given in divided doses or as a single night-time dose (see section 4.4). This may be incrementally increased, under supervision, according to efficacy and tolerance. In general, single doses above 100mg should be avoided in these patients. It is unlikely that 300mg/day will be exceeded. _Paediatric population _ There are insufficient data to recommend the use of Trazodone hydrochloride in children below the age of 18 years. DEPRESSION ACCOMPANIED BY ANXIETY: As for depression. ANXIETY: 75mg/day increasing to 300mg/day as necessary. A decrease in side-effects (increase of the resorption and decrease of the peak plasma concentration) can be reached by taking Trazodone hydrochloride after a meal. _Hepatic Impairment:_ Trazodone hydrochloride undergoes extensive hepatic metabolism, see section 5.2, and has also been associated with hepatotoxicity, see sections 4.4 and 4.8. Therefore caution should be exercised when prescribing for patients with hepatic impairment, particularly in cases of severe hepatic impairment. Periodic monitoring of liver function may be considered. Baca dokumen lengkapnya